Archive · 1 Sep 2026
Symbiotec Pharmalab Shares Set for Premium Market Debut
Symbiotec Pharmalab is a pharmaceutical and biotechnology company based in Indore.
Its shares are scheduled to start trading on the BSE and NSE on 1 September.
Investors paid ₹988 per share in the IPO at the top of the price range.
In the grey market, the shares were recently being discussed at about ₹185 more than that price.
This suggests a possible debut price of around ₹1,173, but it is only an estimate and not a guarantee.
An earlier grey market premium of ₹203 had suggested a higher price of ₹1,191.
The IPO received many applications, especially from large institutional investors.
The company plans to use money from newly issued shares mainly to repay loans and for general business purposes.
Symbiotec Pharmalab shares are scheduled to list on the BSE and NSE on Tuesday, 1 September, with trading from 10 a.m.
The latest grey market premium was ₹185, implying an estimated listing price of ₹1,173, or 18.72% above the ₹988 issue price.
An earlier GMP of ₹203 indicated a possible listing price of ₹1,191, showing that grey market expectations had weakened.
The IPO was subscribed about 75 times overall, including 172.03 times by QIBs, 73.63 times by NIIs and 12.96 times by retail investors.
The ₹1,757 crore issue comprises a ₹150 crore fresh issue for debt repayment and general purposes, plus a ₹1,607 crore offer for sale.
- Who
- Symbiotec Pharmalab, its promoters and selling investors, and investors who subscribed to the IPO.
- What
- Symbiotec Pharmalab shares are scheduled to list after a heavily subscribed IPO, with grey market indications pointing to a possible premium.
- When
- The IPO was open from 24 to 27 August; allotment was finalised on 28 August, and listing is scheduled for Tuesday, 1 September.
- Where
- The shares are scheduled to list on the BSE and NSE; the company is based in Indore.
- Why
- The company is raising ₹150 crore through fresh shares for debt repayment and general corporate purposes, while existing holders are selling shares through the offer for sale.
Premium Outlook
Cautious Outlook
Expected listing price
Premium Outlook
The latest GMP suggested a listing around ₹1,173, while an analyst estimated a 20–22% premium over the issue price.
Cautious Outlook
The GMP fell from ₹203 to ₹185, and its decline over recent sessions suggests that the potential premium could weaken.
Long-term prospects
Premium Outlook
The company’s manufacturing network, R&D capabilities, backward integration, product range, regulatory approvals and capacity expansion were cited as growth strengths.
Cautious Outlook
The stock’s market debut is uncertain because grey market premiums are unofficial indicators and do not guarantee the actual listing price.
Investor strategy
Premium Outlook
Analyst Mahesh M. Ojha said allottees could book partial profits while retaining some shares for long-term participation.
Cautious Outlook
Investors may need to account for the reported downward GMP trend before assuming that the IPO will sustain a premium.
- Issue price
- ₹938–₹988 per equity share; the upper price was ₹988
- Latest GMP
- ₹185, implying an estimated listing price of ₹1,173
- Earlier GMP
- ₹203, implying an estimated listing price of ₹1,191
- Estimated premium
- The latest indication was 18.72% above the ₹988 issue price
- Subscription
- QIBs: 172.03 times; NIIs: 73.63 times; retail investors: 12.96 times; overall subscription was reported at about 75 times
- Issue structure
- ₹150 crore fresh issue and ₹1,607 crore offer for sale, totaling ₹1,757 crore
- Trading details
- Listing on the BSE and NSE, with trading available from 10 a.m.; shares are in the B group of securities according to a BSE notice
